Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study

Summary Background Full‐dose prophylaxis is very effective at minimizing joint damage but is costly. Tailored prophylaxis has been proposed as a way of reducing costs while still protecting joints. Objective To report detailed findings in index joints of 56 subjects with severe hemophilia A entered...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2013-03, Vol.11 (3), p.460-466
Hauptverfasser:	Hilliard, P., Zourikian, N., Blanchette, V., Chan, A., Elliott, B., Israels, S. J., Nilson, J., Poon, M.‐C., Laferriere, N., Van Neste, C., Jarock, C., Wu, J., McLimont, M., Feldman, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomechanical Phenomena Canada Child Child, Preschool Coagulants - administration & dosage Coagulants - adverse effects Disability Evaluation Drug Administration Schedule Factor VIII - administration & dosage Factor VIII - adverse effects hemarthrosis Hemarthrosis - diagnosis Hemarthrosis - etiology Hemarthrosis - physiopathology Hemarthrosis - prevention & control hemophilia Hemophilia A - blood Hemophilia A - complications Hemophilia A - diagnosis Hemophilia A - drug therapy Humans Infant joint Joints - physiopathology Kaplan-Meier Estimate Linear Models Male Muscular Atrophy - etiology Muscular Atrophy - prevention & control Physical Examination prophylaxis Range of Motion, Articular Recombinant Proteins - administration & dosage Severity of Illness Index Surveys and Questionnaires Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background Full‐dose prophylaxis is very effective at minimizing joint damage but is costly. Tailored prophylaxis has been proposed as a way of reducing costs while still protecting joints. Objective To report detailed findings in index joints of 56 subjects with severe hemophilia A entered into the Canadian Hemophilia Prophylaxis Study, and treated with tailored prophylaxis, after 13 years. Methods Boys with severe hemophilia A (
ISSN:	1538-7933 1538-7836 1538-7836
DOI:	10.1111/jth.12113